Veracyte, Inc. - VCYT STOCK NEWS

Veracyte announced positive data on its Percepta Genomic Sequencing Classifier (GSC), published in PLOS ONE. The multi-cohort study involved 412 lung nodule patients with inconclusive bronchoscopy results, demonstrating that the Percepta GSC can accurately reclassify cancer risk, helping patients avoid unnecessary invasive procedures. Results showed that 39.1% of patients were reclassified into different risk categories, with significant predictive values for identifying low and high risks. These findings could potentially lead to earlier diagnoses and improved patient outcomes for lung cancer.

Veracyte (NASDAQ: VCYT) announced findings from a meta-analysis presented at ENDO 2022, reinforcing the Afirma Genomic Sequencing Classifier's (GSC) accuracy in ruling out thyroid cancer in patients with indeterminate nodules. The analysis of 13 studies indicates a sensitivity of 97% and a negative predictive value of 99%, mirroring original clinical validation. Notably, the Afirma GSC showed a 65% positive predictive value for malignancy in suspicious nodules, surpassing the initial 47% noted in earlier validations. This underscores the test's effectiveness in reducing unnecessary surgeries.

Veracyte (Nasdaq: VCYT) announced significant findings from the SAKK 09/10 trial, a phase 3 study involving 226 patients with biochemical recurrence of prostate cancer. The Decipher Prostate genomic classifier demonstrated its ability to identify patients at high risk for cancer progression post-radical prostatectomy, guiding timely and effective treatment decisions. Patients with high Decipher scores were over twice as likely to experience progression. This study supports the utility of Decipher Prostate in personalized treatment strategies, enhancing patient outcomes.

New data from Veracyte's Immunoscore Immune Checkpoint assay indicates potential for improving treatment of metastatic colorectal cancer (mCRC) by identifying patients likely to benefit from immune checkpoint inhibitors. Findings from the AtezoTRIBE trial, published in The Lancet Oncology, show a modest benefit when atezolizumab is added to standard treatment. The study reveals a significant correlation between high Immunoscore IC results and treatment response, marking it as a potential predictive tool for mCRC patients.

Veracyte announced new data from a significant study involving over 10,000 men, highlighting the clinical utility of the Decipher Prostate genomic classifier. The findings suggest that Decipher tests can effectively guide prostate cancer treatment decisions, leading to improved patient care. Results indicate that men with low-risk scores are more likely to choose active surveillance, whereas those with higher-risk scores tend to opt for radical prostatectomy. This collaboration aims to enhance data for oncology researchers through the National Cancer Institute's SEER program.

Veracyte, Inc. (Nasdaq: VCYT) announced data from a clinical study showcasing the Immunoscore Immune Checkpoint (IC) assay's ability to predict which patients with metastatic non-small cell lung cancer (NSCLC) may benefit from immune checkpoint inhibitors (ICIs). Presented at the ASCO Annual Meeting on June 6, the study involved 265 patients, revealing that 100% of those with a high-risk score relapsed within 18 months, while a significant proportion of low-risk patients did not relapse for at least 36 months. The findings aim to enhance patient selection in clinical trials and optimize treatment approaches.

Veracyte (Nasdaq: VCYT) has announced CEO Marc Stapley and CFO Rebecca Chambers will present at the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 10:40 a.m. PT, and at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 2:40 p.m. PT. Live audio webcasts will be accessible on Veracyte's website, with replays available for 90 days post-event. Veracyte is a global diagnostics firm focused on improving patient care through advanced diagnostic tests that address prevalent cancers and reduce unnecessary procedures.

Veracyte, Inc. (NASDAQ: VCYT) has presented new data on its Percepta Nasal Swab test at the American Thoracic Society 2022 International Conference. The test accurately assesses lung cancer risk in current and former smokers with lung nodules, irrespective of their smoking history. The study involved 291 smokers and highlighted its 96% sensitivity and 94% specificity for identifying high-risk nodules. The data suggests potential for reducing unnecessary procedures and facilitating timely treatment for lung cancer patients. Veracyte aims to enhance clinical utility evidence for reimbursement.